Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

BACKGROUND: High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD Treatment (PREFECT) study, we assessed the effect of reducing intestinal phosphate a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ureña-Torres, Pablo, Prié, Dominique, Keddad, Karim, Preston, Peter, Wilde, Paul, Wan, Hong, Copley, J Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107721/
https://www.ncbi.nlm.nih.gov/pubmed/24885942
http://dx.doi.org/10.1186/1471-2369-15-71

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107721/
https://www.ncbi.nlm.nih.gov/pubmed/24885942
http://dx.doi.org/10.1186/1471-2369-15-71

Ejemplares similares